

# Markus Peter Schlaich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3240546/publications.pdf>

Version: 2024-02-01

374  
papers

28,348  
citations

10986  
71  
h-index

6471  
157  
g-index

377  
all docs

377  
docs citations

377  
times ranked

20272  
citing authors

#	ARTICLE	IF	CITATIONS
1	2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. Journal of Human Hypertension, 2023, 37, 428-437.	2.2	22
2	Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPPLICITY Registry with follow-up data of 3 years. Nephrology Dialysis Transplantation, 2022, 37, 304-310.	0.7	22
3	MicroRNA-132 may be associated with blood pressure and liver steatosisâ€”preliminary observations in obese individuals. Journal of Human Hypertension, 2022, 36, 911-916.	2.2	8
4	No Evidence for Long Term Blood Pressure Differences Between Eversion and Conventional Carotid Endarterectomy in Two Independent Study Cohorts. European Journal of Vascular and Endovascular Surgery, 2022, 63, 33-42.	1.5	2
5	Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage. Hypertension, 2022, 79, 261-270.	2.7	2
6	K-means panning â€œ Developing a new standard in automated MSNA signal recognition with a weakly supervised learning approach. Computers in Biology and Medicine, 2022, 140, 105087.	7.0	1
7	Renal denervation alters ambulatory blood pressure-derived salt sensitivity index in patients with uncontrolled hypertension. Journal of Hypertension, 2022, 40, 570-578.	0.5	3
8	Automatic data extraction from 24 hour blood pressure measurement reports of a large multicenter clinical trial. Computer Methods and Programs in Biomedicine, 2022, 214, 106588.	4.7	2
9	Hypertension With Negative Metaiodobenzylguanidine Scintigraphy. Hypertension, 2022, 79, 474-478.	2.7	1
10	The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy. Biomedicines, 2022, 10, 522.	3.2	8
11	Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy. Bioscience Reports, 2022, 42, .	2.4	20
12	Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition. Current Hypertension Reports, 2022, 24, 67-74.	3.5	11
13	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation, 2022, 145, 847-863.	1.6	28
14	Retinal Capillary Damage Is Already Evident in Patients With Hypertension and Prediabetes and Associated With HbA1c Levels in the Nondiabetic Range. Diabetes Care, 2022, 45, 1472-1475.	8.6	3
15	Autoencoded deep features for semi-automatic, weakly supervised physiological signal labelling. Computers in Biology and Medicine, 2022, 143, 105294.	7.0	1
16	Uncontrolled blood pressure in Australia: a call to action. Medical Journal of Australia, 2022, 216, 61-63.	1.7	11
17	Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system. Current Opinion in Nephrology and Hypertension, 2022, 31, 135-141.	2.0	4
18	Circulating plateletâ€‘derived extracellular vesicles correlate with nightâ€‘time blood pressure and vascular organ damage and may represent an integrative biomarker of vascular health. Journal of Clinical Hypertension, 2022, 24, 738-749.	2.0	5

#	ARTICLE	IF	CITATIONS
19	Global Impact of Different Blood Pressure Thresholds in 690 Participants of the May Measurement Month Initiative. <i>Hypertension</i> , 2022, 79, 1497-1505.	2.7	4
20	Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan. <i>Journal of Clinical Hypertension</i> , 2022, 24, 804-813.	2.0	8
21	Hypertension in stroke survivors and associations with national premature stroke mortality: data for 2.5 million participants from multinational screening campaigns. <i>The Lancet Global Health</i> , 2022, 10, e1141-e1149.	6.3	10
22	Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. <i>American Heart Journal</i> , 2021, 231, 56-67.	2.7	14
23	Sympathetic hyperactivity after coronary artery bypass graft surgery: an important player in the development of postoperative atrial fibrillation?. <i>Europace</i> , 2021, 23, 158-158.	1.7	1
24	Supine blood pressure—A clinically relevant determinant of vascular target organ damage in hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2021, 23, 44-52.	2.0	3
25	Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension. <i>BMJ Open</i> , 2021, 11, e043625.	1.9	11
26	Delayed retinal vein recovery responses indicate both non-adaptation to stress as well as increased risk for stroke: the SABPA study. <i>Cardiovascular Journal of Africa</i> , 2021, 32, 7-18.	0.4	5
27	Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model. <i>Clinical Research in Cardiology</i> , 2021, 110, 740-753.	3.3	10
28	Plasma lipocalin-2/NGAL is stable over 12 weeks and is not modulated by exercise or dieting. <i>Scientific Reports</i> , 2021, 11, 4056.	3.3	7
29	Effects of testosterone treatment, with and without exercise training, on ambulatory blood pressure in middle-aged and older men. <i>Clinical Endocrinology</i> , 2021, 95, 176-186.	2.4	11
30	Role of the sympathetic nervous system in cardiometabolic control: implications for targeted multiorgan neuromodulation approaches. <i>Journal of Hypertension</i> , 2021, 39, 1478-1489.	0.5	5
31	Increase in Bioavailability of Nitric Oxide After Renal Denervation Improves Kidney Function in Sheep With Hypertensive Kidney Disease. <i>Hypertension</i> , 2021, 77, 1299-1310.	2.7	7
32	Device Therapy of Hypertension. <i>Circulation Research</i> , 2021, 128, 1080-1099.	4.5	33
33	Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4241.	4.1	21
34	Diabetic kidney disease in type 2 diabetes: a review of pathogenic mechanisms, patient-related factors and therapeutic options. <i>PeerJ</i> , 2021, 9, e11070.	2.0	6
35	Capillary vascular density in the retina of hypertensive patients is associated with a non-dipping pattern independent of mean ambulatory blood pressure. <i>Journal of Hypertension</i> , 2021, 39, 1826-1834.	0.5	9
36	Features of antihypertensive therapy and real-world prescription of selective imidazoline receptor agonists in Russia vs other countries: STRAIGHT study data analysis. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 440-448.	0.8	6

#	ARTICLE	IF	CITATIONS
37	May Measurement Month 2019: results of blood pressure screening from 47 countries. European Heart Journal Supplements, 2021, 23, B1-B5.	0.1	13
38	Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes. Bioscience Reports, 2021, 41, .	2.4	10
39	May Measurement Month 2019: an analysis of blood pressure screening results from Australia. European Heart Journal Supplements, 2021, 23, B18-B20.	0.1	3
40	Therapeutic inertia in hypertension management – status quo in primary care. Journal of Hypertension, 2021, 39, 1107-1108.	0.5	4
41	Homocysteine predicts vascular target organ damage in hypertension and may serve as guidance for first-line antihypertensive therapy. Journal of Clinical Hypertension, 2021, 23, 1380-1389.	2.0	5
42	Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension, 2021, 77, 1825-1844.	2.7	26
43	Bexagliflozin for type 2 diabetes: an overview of the data. Expert Opinion on Pharmacotherapy, 2021, 22, 2095-2103.	1.8	9
44	European Society of Hypertension position paper on renal denervation 2021. Journal of Hypertension, 2021, 39, 1733-1741.	0.5	88
45	Blunted natriuretic response to saline loading in sheep with hypertensive kidney disease following radiofrequency catheter-based renal denervation. Scientific Reports, 2021, 11, 14795.	3.3	1
46	Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients. Journal of Human Hypertension, 2021, , .	2.2	1
47	Renal denervation as a management strategy for hypertension: current evidence and recommendations. Expert Review of Cardiovascular Therapy, 2021, 19, 825-835.	1.5	0
48	Relationship Between the Aldosterone-to-Renin Ratio and Blood Pressure in Young Adults: A Longitudinal Study. Hypertension, 2021, 78, 387-396.	2.7	6
49	Machine learning powered tools for automated analysis of muscle sympathetic nerve activity recordings. Physiological Reports, 2021, 9, e14996.	1.7	2
50	Female Gender Is Associated with Higher Susceptibility of Weight Induced Arterial Stiffening and Rise in Blood Pressure. Journal of Clinical Medicine, 2021, 10, 3479.	2.4	12
51	Towards Establishing Renal Denervation as the Third Pillar in Hypertension Treatment: The RADIANCE-HTN TRIO Trial. CardioVascular and Interventional Radiology, 2021, 44, 2015-2017.	2.0	0
52	Renal Deafferentation Prevents Progression of Hypertension and Changes to Sympathetic Reflexes in a Rabbit Model of Chronic Kidney Disease. Hypertension, 2021, 78, 1310-1321.	2.7	2
53	Renal, Cardiac, and Autonomic Effects of Catheter-Based Renal Denervation in Ovine Heart Failure. Hypertension, 2021, 78, 706-715.	2.7	5
54	Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet, The, 2021, 398, 1043-1052.	13.7	74

#	ARTICLE	IF	CITATIONS
55	TNFSF14-Derived Molecules as a Novel Treatment for Obesity and Type 2 Diabetes. International Journal of Molecular Sciences, 2021, 22, 10647.	4.1	2
56	Retinal capillary rarefaction is associated with arterial and kidney damage in hypertension. Scientific Reports, 2021, 11, 1001.	3.3	13
57	Increased pulse wave velocity in patients with an orthostatic blood pressure rise independent of other cardiovascular risk factors. Journal of Hypertension, 2021, 39, 1352-1360.	0.5	7
58	Nocturnal hypertension: a common phenotype in a tertiary clinical setting associated with increased arterial stiffness and central blood pressure. Journal of Hypertension, 2021, 39, 250-258.	0.5	10
59	Microvascular changes at different stages of chronic kidney disease. Journal of Clinical Hypertension, 2021, 23, 309-316.	2.0	5
60	A standardized protocol for evaluation of large extracellular vesicles using the attuneâ„¢ NXT system. Journal of Immunological Methods, 2021, 499, 113170.	1.4	5
61	Lipoprotein (a) and Hypertension. Current Hypertension Reports, 2021, 23, 44.	3.5	10
62	Successful renal denervation decreases the platelet activation status in hypertensive patients. Cardiovascular Research, 2020, 116, 202-210.	3.8	13
63	Shades of grey: a matter relevant to sympathetic activity and blood pressure control?. Journal of Hypertension, 2020, 38, 206-207.	0.5	0
64	Does sympathetic hyperactivity adversely impact on the effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure?. Europace, 2020, 22, 331-331.	1.7	0
65	Does sympathetic hyperactivity adversely impact on the effect of pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation?. Europace, 2020, 22, 506-506.	1.7	0
66	Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. Journal of Hypertension, 2020, 38, 377-386.	0.5	7
67	Ambulatory blood pressure monitoring and morning surge in blood pressure in adult black and white South Africans. Journal of Clinical Hypertension, 2020, 22, 21-28.	2.0	5
68	The role of selective imidazoline receptor agonists in modern hypertension management: an international real-world survey (STRAIGHT). Current Medical Research and Opinion, 2020, 36, 1939-1945.	1.9	3
69	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	13.7	3,928
70	May Measurement Month 2018: results of blood pressure screening from 41 countries. European Heart Journal Supplements, 2020, 22, H1-H4.	0.1	5
71	May Measurement Month 2018: an analysis of blood pressure screening results from Australia. European Heart Journal Supplements, 2020, 22, H17-H19.	0.1	4
72	Renal denervation as a synergistic tool for the treatment of polymorphic ventricular ectopic beats. Medicine (United States), 2020, 99, e21098.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Interventional Approaches for Loin Pain Hematuria Syndrome and Kidney-Related Pain Syndromes. Current Hypertension Reports, 2020, 22, 103.	3.5	4
74	SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging. Biomedicines, 2020, 8, 514.	3.2	11
75	Modification of diet, exercise and lifestyle (MODEL) study: a randomised controlled trial protocol. BMJ Open, 2020, 10, e036366.	1.9	6
76	Implementation, mechanisms of impact and key contextual factors involved in outcomes of the Modification of Diet, Exercise and Lifestyle (MODEL) randomised controlled trial in Australian adults: protocol for a mixed-method process evaluation. BMJ Open, 2020, 10, e036395.	1.9	0
77	Differential sympathetic response to lesion-induced chronic kidney disease in rabbits. Kidney International, 2020, 98, 906-917.	5.2	3
78	Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement. Medical Journal of Australia, 2020, 213, 182-187.	1.7	54
79	The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF- $\alpha$ . Journal of Clinical Medicine, 2020, 9, 2764.	2.4	4
80	Contribution of the Renal Nerves to Hypertension in a Rabbit Model of Chronic Kidney Disease. Hypertension, 2020, 76, 1470-1479.	2.7	8
81	Vascular compression of the rostral ventrolateral medulla: a relevant indicator of sympathetically driven blood pressure variability?. Journal of Hypertension, 2020, 38, 2380-2381.	0.5	1
82	May Measurement Month 2019. Hypertension, 2020, 76, 333-341.	2.7	157
83	2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 2020, 75, 1334-1357.	2.7	1,895
84	2020 International Society of Hypertension global hypertension practice guidelines. Journal of Hypertension, 2020, 38, 982-1004.	0.5	452
85	Renal Denervation in High-Risk Patients With Hypertension. Journal of the American College of Cardiology, 2020, 75, 2879-2888.	2.8	80
86	SGLT2 Inhibitor-Induced Sympathoinhibition. JACC Basic To Translational Science, 2020, 5, 169-179.	4.1	152
87	The role of afferent renal denervation in renovascular hypertension—another brick in the wall. Pflügers Archiv European Journal of Physiology, 2020, 472, 323-324.	2.8	1
88	White Coat Hypertension—A Case for Assessing Vascular Age?. American Journal of Hypertension, 2020, 33, 599-601.	2.0	0
89	An evaluation of empagliflozin and its applicability to hypertension as a therapeutic option. Expert Opinion on Pharmacotherapy, 2020, 21, 1157-1166.	1.8	4
90	Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. World Journal of Gastroenterology, 2020, 26, 3225-3235.	3.3	17

#	ARTICLE	IF	CITATIONS
91	The Schlager mouse as a model of altered retinal phenotype. <i>Neural Regeneration Research</i> , 2020, 15, 512.	3.0	6
92	Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice. <i>World Journal of Gastroenterology</i> , 2020, 26, 3225-3235.	3.3	0
93	Renal Denervation: Physiology, Scope, and Current Evidence. , 2020, , 349-366.		0
94	Reply. <i>Journal of Hypertension</i> , 2020, 38, 2339-2340.	0.5	0
95	The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension. <i>British Journal of Pharmacology</i> , 2019, 176, 1839-1852.	5.4	51
96	Effects of sympathetic modulation in metabolic disease. <i>Annals of the New York Academy of Sciences</i> , 2019, 1454, 80-89.	3.8	27
97	Multivariable Analysis of Patients With Severe Persistent Postprocedural Hypotension After Carotid Artery Stenting. <i>Journal of Endovascular Therapy</i> , 2019, 26, 759-767.	1.5	8
98	New insights about post-exercise albuminuria in hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1180-1182.	2.0	1
99	Effect of Pupil Dilation with Tropicamide on Retinal Vascular Caliber. <i>Ophthalmic Epidemiology</i> , 2019, 26, 400-407.	1.7	10
100	Renal Denervation for Treating Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1095-1105.	2.9	61
101	Sympathetic activity in obesity: a brief review of methods and supportive data. <i>Annals of the New York Academy of Sciences</i> , 2019, 1454, 56-67.	3.8	17
102	Renal denervation for treating congenital long QT syndrome: shortening the QT interval or modulating sympathetic tone?. <i>Europace</i> , 2019, 21, 1755-1756.	1.7	2
103	New Molecules for Treating Resistant Hypertension: a Clinical Perspective. <i>Current Hypertension Reports</i> , 2019, 21, 80.	3.5	5
104	Android Fat Deposition and Its Association With Cardiovascular Risk Factors in Overweight Young Males. <i>Frontiers in Physiology</i> , 2019, 10, 1162.	2.8	29
105	Sustained Decrease in Blood Pressure and Reduced Anatomical and Functional Reinnervation of Renal Nerves in Hypertensive Sheep 30 Months After Catheter-Based Renal Denervation. <i>Hypertension</i> , 2019, 73, 718-727.	2.7	57
106	Renal Denervation Update From the International Sympathetic Nervous System Summit. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3006-3017.	2.8	74
107	Blunted diuretic and natriuretic responses to acute sodium loading early after catheter-based renal denervation in normotensive sheep. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2019, 317, R319-R327.	1.8	6
108	May Measurement Month 2017: Results of 39 national blood pressure screening programmes. <i>European Heart Journal Supplements</i> , 2019, 21, D1-D4.	0.1	13



#	ARTICLE	IF	CITATIONS
109	Obesity-Associated Organ Damage and Sympathetic Nervous Activity. Hypertension, 2019, 73, 1150-1159.	2.7	30
110	New Approaches in the Management of Sudden Cardiac Death in Patients with Heart Failureâ€”Targeting the Sympathetic Nervous System. International Journal of Molecular Sciences, 2019, 20, 2430.	4.1	24
111	May Measurement Month 2017: an analysis of the blood pressure screening campaign results in Indonesiaâ€”South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D63-D65.	0.1	4
112	May Measurement Month 2017: an analysis of blood pressure screening results from Australiaâ€”South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D14-D16.	0.1	6
113	Blood pressure screening during the May Measurement Month 2017 programme in Vietnamâ€”South-East Asia and Australasia. European Heart Journal Supplements, 2019, 21, D127-D129.	0.1	6
114	Facies, depositional environments, and anatomy of the Subis build-up in Sarawak, Malaysia: implications on other Miocene isolated carbonate build-ups. Facies, 2019, 65, 1.	1.4	17
115	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal, 2019, 40, 2006-2017.	2.2	193
116	Relevance of Targeting the Distal Renal Artery and Branches with Radiofrequency Renal Denervation Approachesâ€”A Secondary Analysis from a Hypertensive CKD Patient Cohort. Journal of Clinical Medicine, 2019, 8, 581.	2.4	6
117	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPPLICITY Registry. European Heart Journal, 2019, 40, 3474-3482.	2.2	189
118	Current Knowledge of IL-6 Cytokine Family Members in Acute and Chronic Kidney Disease. Biomedicines, 2019, 7, 19.	3.2	24
119	Self-monitoring of blood pressure to guide titration of antihypertensive medicationâ€”a new era in hypertension management?. Cardiovascular Diagnosis and Therapy, 2019, 9, 94-99.	1.7	4
120	Diuretics and skin cancer. Journal of Hypertension, 2019, 37, 1961-1962.	0.5	0
121	Shaping the future of renal denervation-the relevance of sham-controlled randomized trials and recent meta-analyses. Cardiovascular Diagnosis and Therapy, 2019, 9, 601-606.	1.7	1
122	Seismic architecture of a Miocene isolated carbonate platform and associated off-platform strata (Central Luconia Province, offshore Malaysia). Marine and Petroleum Geology, 2019, 102, 477-495.	3.3	36
123	Sympathetic Activation in Hypertensive Chronic Kidney Disease â€” A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?. Frontiers in Physiology, 2019, 10, 1546.	2.8	18
124	Sympathetic stimulation with norepinephrine may come at a cost. Neural Regeneration Research, 2019, 14, 977.	3.0	5
125	The molecular basis for the neutral effect of renal denervation in patients with chronic heart failure not responding to cardiac resynchronisation therapy â€” a perspective. Postępy W Kardiologii Interwencyjnej, 2019, 15, 503-504.	0.2	0
126	Resistant Hypertension: Which Agent?. Heart Lung and Circulation, 2018, 27, 911-916.	0.4	2



#	ARTICLE	IF	CITATIONS
127	A polymorphism in the noradrenaline transporter gene is associated with increased blood pressure in patients with resistant hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1571-1577.	0.5	19
128	May measurement month 2017—a concerted global effort to raise awareness of elevated blood pressure. <i>Journal of Human Hypertension</i> , 2018, 32, 319-320.	2.2	1
129	Pharmacotherapeutic strategies for treating hypertension in patients with obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 643-651.	1.8	9
130	Inverse association between sympathetic nervous system activity and bone mass in middle aged overweight individuals. <i>Bone</i> , 2018, 111, 123-128.	2.9	10
131	Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial. <i>Clinical Research in Cardiology</i> , 2018, 107, 642-652.	3.3	17
132	Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation*. <i>Journal of Hypertension</i> , 2018, 36, 1414-1422.	0.5	26
133	Shining LIGHT on the metabolic role of the cytokine TNFSF14 and the implications on hepatic IL-6 production. <i>Immunology and Cell Biology</i> , 2018, 96, 41-53.	2.3	16
134	Obesity Paradox in Hypertension. <i>Hypertension</i> , 2018, 71, 22-33.	2.7	50
135	Suitability for catheter-based renal denervation—lessons from “super-responders”. <i>Journal of Hypertension</i> , 2018, 36, 1475-1476.	0.5	0
136	Reply. <i>Journal of Hypertension</i> , 2018, 36, 1606-1607.	0.5	0
137	Stressing the metabolic powers of fibroblast growth factor 21. <i>AME Medical Journal</i> , 2018, 3, 97-97.	0.4	1
138	Comparison of Commonly Used Questionnaires to Identify Obstructive Sleep Apnea in a High-Risk Population. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 2057-2064.	2.6	18
139	Autonomic Regulation of Glucose Homeostasis: a Specific Role for Sympathetic Nervous System Activation. <i>Current Diabetes Reports</i> , 2018, 18, 107.	4.2	30
140	Catheter-based renal denervation: the next chapter begins. <i>European Heart Journal</i> , 2018, 39, 4144-4149.	2.2	21
141	May Measurement Month 2017: an analysis of blood pressure screening results worldwide. <i>The Lancet Global Health</i> , 2018, 6, e736-e743.	6.3	245
142	Are the American Heart Association/American College of Cardiology High Blood Pressure Guidelines Fit for Global Purpose?: Thoughts From the International Society of Hypertension. <i>Hypertension</i> , 2018, 72, 260-262.	2.7	20
143	Renal Denervation—Ready for Prime Time!?. <i>Hypertension</i> , 2018, 72, 287-290.	2.7	12
144	Role of the Sympathetic Nervous System and Its Modulation in Renal Hypertension. <i>Frontiers in Medicine</i> , 2018, 5, 82.	2.6	104

#	ARTICLE	IF	CITATIONS
145	Renal denervation: one step backwards, three steps forward. <i>Nature Reviews Nephrology</i> , 2018, 14, 602-604.	9.6	5
146	Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-8.	1.5	19
147	A cautionary note for researchers treating mice with the neurotransmitter norepinephrine. <i>Biochemistry and Biophysics Reports</i> , 2018, 15, 103-106.	1.3	4
148	Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation. <i>Frontiers in Neuroscience</i> , 2018, 12, 1058.	2.8	40
149	Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension. <i>EuroIntervention</i> , 2018, 14, 121-128.	3.2	19
150	Renalase “a potential biomarker for risk of atrial fibrillation?”. <i>Kardiologia Polska</i> , 2018, 76, 1201-1202.	0.6	3
151	A polymorphism in the norepinephrine transporter gene is associated with affective and cardiovascular disease through a microRNA mechanism. <i>Molecular Psychiatry</i> , 2017, 22, 134-141.	7.9	38
152	Effect of renal denervation on kidney function in patients with chronic kidney disease. <i>International Journal of Cardiology</i> , 2017, 232, 93-97.	1.7	56
153	The role of renal sympathetic nerves in ischemia reperfusion injury. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017, 204, 105-111.	2.8	19
154	Catheter-Based Renal Denervation Exacerbates Blood Pressure Fall During Hemorrhage. <i>Journal of the American College of Cardiology</i> , 2017, 69, 951-964.	2.8	40
155	Renal denervation in less severe forms of (resistant) hypertension “Quo vadis?”. <i>Journal of Clinical Hypertension</i> , 2017, 19, 369-370.	2.0	1
156	Serum uric acid and the relationship with subclinical organ damage in adults. <i>Journal of Hypertension</i> , 2017, 35, 745-752.	0.5	10
157	Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension. <i>Journal of Hypertension</i> , 2017, 35, 148-153.	0.5	23
158	Sympathetic Response and Outcomes Following Renal Denervation in Patients With Chronic Heart Failure: 12-Month Outcomes From the Symplicity HF Feasibility Study. <i>Journal of Cardiac Failure</i> , 2017, 23, 702-707.	1.7	44
159	Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. <i>Journal of Hypertension</i> , 2017, 35, 2059-2068.	0.5	150
160	Renal Sympathetic Denervation: A Viable Option for Treating Resistant Hypertension. <i>American Journal of Hypertension</i> , 2017, 30, 847-856.	2.0	16
161	Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?. <i>Current Hypertension Reports</i> , 2017, 19, 30.	3.5	3
162	Response to Letter to the Editor by Drs. Yang and Yu entitled: Renal denervation in patients with chronic kidney disease. <i>International Journal of Cardiology</i> , 2017, 235, 190.	1.7	0

#	ARTICLE	IF	CITATIONS
163	Renal Denervation Reduces Monocyte Activation and Monocyteâ€Platelet Aggregate Formation. Hypertension, 2017, 69, 323-331.	2.7	61
164	Muscle Sympathetic Nerve Activity Is Associated With Elements of the Plasma Lipidomic Profile in Young Asian Adults. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2059-2068.	3.6	8
165	Hypertension on the ROX. Hypertension, 2017, 70, 1084-1086.	2.7	2
166	Renal Denervation: Current Opinions and Practice. , 2017, , 419-426.		0
167	Renal Denervation After the SPYRAL HTN-OFF MED Trial. Hypertension, 2017, 70, 1076-1079.	2.7	5
168	Effects of Moxonidine and Lowâ€Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies. Obesity, 2017, 25, 1894-1902.	3.0	21
169	The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension. Current Hypertension Reports, 2017, 19, 99.	3.5	16
170	Soluble vascular endothelial growth factor receptor-1 is reduced in patients with resistant hypertension after renal denervation. Journal of Human Hypertension, 2017, 31, 248-252.	2.2	5
171	Neck Circumference Is Associated with Muscle Sympathetic Nerve Activity in Overweight and Obese Men but Not Women. Frontiers in Physiology, 2017, 8, 203.	2.8	6
172	The Effect of Renal Denervation on Plasma Adipokine Profile in Patients with Treatment Resistant Hypertension. Frontiers in Physiology, 2017, 8, 369.	2.8	9
173	Endothelial Function in Healthy Young Individuals Is Associated with Dietary Consumption of Saturated Fat. Frontiers in Physiology, 2017, 8, 876.	2.8	18
174	The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice. International Journal of Molecular Sciences, 2017, 18, 884.	4.1	10
175	ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice. Mediators of Inflammation, 2017, 2017, 1-9.	3.0	9
176	Three-year changes of prothrombotic factors in a cohort of South Africans with a high clinical suspicion of obstructive sleep apnea. Thrombosis and Haemostasis, 2016, 115, 63-72.	3.4	14
177	Guideline for the diagnosis and management of hypertension in adults â€” 2016. Medical Journal of Australia, 2016, 205, 85-89.	1.7	236
178	Microalbuminuria â€” an important marker of residual risk. Journal of Hypertension, 2016, 34, 627-628.	0.5	1
179	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension. Journal of Hypertension, 2016, 34, 2480-2486.	0.5	19
180	What we need to know about renal nerve ablation for treatment of hypertension and other states of sympathetic overactivity. American Journal of Physiology - Renal Physiology, 2016, 311, F1267-F1270.	2.7	9

#	ARTICLE	IF	CITATIONS
181	Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial. American Journal of Clinical Nutrition, 2016, 103, 1426-1433.	4.7	101
182	Chronic depression symptoms and salivary NOx are associated with retinal vascular dysregulation: The SABPA study. Nitric Oxide - Biology and Chemistry, 2016, 55-56, 10-17.	2.7	22
183	Residual Sympathetic Responsiveness After Catheter-Based Renal Denervation. Hypertension, 2016, 67, 1117-1118.	2.7	3
184	Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clinical Research in Cardiology, 2016, 105, 755-762.	3.3	21
185	Is it time to think about the sodium glucose co-transporter 2 sympathetically?. Nephrology, 2016, 21, 286-294.	1.6	21
186	Anatomical and procedural determinants of catheter-based renal denervation. Cardiovascular Revascularization Medicine, 2016, 17, 474-479.	0.8	13
187	Sympathetic nervous response to ischemia-reperfusion injury in humans is altered with remote ischemic preconditioning. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H364-H370.	3.2	41
188	Renal Nitric Oxide Deficiency and Chronic Kidney Disease in Young Sheep Born with a Solitary Functioning Kidney. Scientific Reports, 2016, 6, 26777.	3.3	20
189	Device Therapies for Resistant Hypertension. Clinical Therapeutics, 2016, 38, 2152-2158.	2.5	7
190	Renal denervation for resistant hypertension. Journal of Hypertension, 2016, 34, 1505-1506.	0.5	1
191	Overexpression and knock-down studies highlight that a disintegrin and metalloproteinase 28 controls proliferation and migration in human prostate cancer. Medicine (United States), 2016, 95, e5085.	1.0	10
192	Impact of nurse-mediated management on achieving blood pressure goal levels in primary care: Insights from the Valsartan Intensified Primary care Reduction of Blood Pressure Study. European Journal of Cardiovascular Nursing, 2016, 15, 409-416.	0.9	8
193	Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer. BMC Cancer, 2016, 16, 151.	2.6	14
194	Central Sympathetic Inhibition: a Neglected Approach for Treatment of Cardiac Arrhythmias?. Current Hypertension Reports, 2016, 18, 13.	3.5	5
195	The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 344-352.	2.0	21
196	Renal artery anatomy affects the blood pressure response to renal denervation in patients with resistant hypertension. International Journal of Cardiology, 2016, 202, 388-393.	1.7	20
197	Reduction in peripheral vascular resistance predicts improvement in insulin clearance following weight loss. Cardiovascular Diabetology, 2015, 14, 113.	6.8	13
198	Health-related quality of life and blood pressure 12 months after renal denervation. Journal of Hypertension, 2015, 33, 2350-2358.	0.5	7

#	ARTICLE	IF	CITATIONS
199	Sympathetic activation and endothelial dysfunction in polycystic ovary syndrome are not explained by either obesity or insulin resistance. <i>Clinical Endocrinology</i> , 2015, 83, 812-819.	2.4	60
200	New developments in the pathogenesis of obesity-induced hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1499-1508.	0.5	68
201	Device-based approaches for renal nerve ablation for hypertension and beyond. <i>Frontiers in Physiology</i> , 2015, 6, 193.	2.8	12
202	Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-11.	2.3	273
203	Reverse cardiac remodeling after renal denervation: Atrial electrophysiologic and structural changes associated with blood pressure lowering. <i>Heart Rhythm</i> , 2015, 12, 982-990.	0.7	58
204	Arterial Norepinephrine Concentration is Inversely and Independently Associated With Insulin Clearance in Obese Individuals With Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1544-1550.	3.6	16
205	Central arteriovenous anastomosis in resistant hypertension?. <i>Lancet, The</i> , 2015, 385, 1596-1597.	13.7	7
206	Reinnervation following catheter-based radiofrequency renal denervation. <i>Experimental Physiology</i> , 2015, 100, 485-490.	2.0	32
207	First Report of the Global SYMPPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension. <i>Hypertension</i> , 2015, 65, 766-774.	2.7	172
208	The effect of renal denervation on endothelial function and inflammatory markers in patients with resistant hypertension. <i>International Journal of Cardiology</i> , 2015, 188, 96-98.	1.7	12
209	Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 797-803.	3.4	6
210	The Role of Central Nervous System Mechanisms in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2015, 17, 58.	3.5	26
211	Short-term effects of catheter-based renal denervation on cardiac sympathetic drive and cardiac baroreflex function in heart failure. <i>International Journal of Cardiology</i> , 2015, 190, 220-226.	1.7	20
212	Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2015, 104, 672-678.	3.3	42
213	Opposing effects of shear-mediated dilation and myogenic constriction on artery diameter in response to handgrip exercise in humans. <i>Journal of Applied Physiology</i> , 2015, 119, 858-864.	2.5	23
214	Role of the Sympathetic Nervous System in Stress-Mediated Cardiovascular Disease. <i>Current Hypertension Reports</i> , 2015, 17, 80.	3.5	82
215	Metabolic syndrome: a sympathetic disease?. <i>Lancet Diabetes and Endocrinology, the</i> , 2015, 3, 148-157.	11.4	118
216	Reinnervation of Renal Afferent and Efferent Nerves at 5.5 and 11 Months After Catheter-Based Radiofrequency Renal Denervation In Sheep. <i>Hypertension</i> , 2015, 65, 393-400.	2.7	140

#	ARTICLE	IF	CITATIONS
217	Renal Denervation: Potential Future Implications Beyond Resistant Hypertension. , 2015, , 155-161.		0
218	The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease. , 2015, , 181-189.		0
219	Renal denervation: current implications and future perspectives. Clinical Science, 2014, 126, 41-53.	4.3	24
220	Sympathetic Activity and Markers of Cardiovascular Risk in Nondiabetic Severely Obese Patients: The Effect of the Initial 10% Weight Loss. American Journal of Hypertension, 2014, 27, 1308-1315.	2.0	34
221	Response to Letter Regarding Article, “Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension” Circulation, 2014, 129, e500-1.	1.6	0
222	Rebuttal from Markus P. Schlaich, Yusuke Sata and Murray D. Esler. Journal of Physiology, 2014, 592, 3947-3947.	2.9	0
223	Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. European Heart Journal, 2014, 35, 2224-2231.	2.2	140
224	Treatment-resistant hypertension—a risk factor for ESRD. Nature Reviews Nephrology, 2014, 10, 189-190.	9.6	1
225	Response to More Research Is Needed to Investigate the Effect of Denervation on Blood Pressure. Hypertension, 2014, 63, e86.	2.7	0
226	CrossTalk opposing view: Which technique for controlling resistant hypertension? Renal nerve ablation. Journal of Physiology, 2014, 592, 3937-3940.	2.9	5
227	Regulation of the sympathetic nervous system by the kidney. Current Opinion in Nephrology and Hypertension, 2014, 23, 61-68.	2.0	14
228	The effects of dietary weight loss on indices of norepinephrine turnover: Modulatory influence of hyperinsulinemia. Obesity, 2014, 22, 652-662.	3.0	19
229	Baroreflex Sensitivity. Journal of the American College of Cardiology, 2014, 64, 232-233.	2.8	0
230	Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. Amino Acids, 2014, 46, 321-326.	2.7	28
231	Association of vitamin D status and blood pressure response after renal denervation. Clinical Research in Cardiology, 2014, 103, 41-47.	3.3	19
232	Sustained Sympathetic and Blood Pressure Reduction 1 Year After Renal Denervation in Patients With Resistant Hypertension. Hypertension, 2014, 64, 118-124.	2.7	132
233	Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet, The, 2014, 383, 622-629.	13.7	556
234	Morning Surge in Blood Pressure Is Associated With Reactivity of the Sympathetic Nervous System. American Journal of Hypertension, 2014, 27, 783-792.	2.0	47

#	ARTICLE	IF	CITATIONS
235	Targeting the Sympathetic Nervous System. Hypertension, 2014, 63, 426-432.	2.7	29
236	Biomarkers for the Prediction of Blood Pressure Response to Renal Denervation. Hypertension, 2014, 63, 907-908.	2.7	5
237	A Randomized Controlled Trial of the Effects of Pioglitazone Treatment on Sympathetic Nervous System Activity and Cardiovascular Function in Obese Subjects With Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1701-E1707.	3.6	22
238	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPPLICITY HTN-2 randomized clinical trial. European Heart Journal, 2014, 35, 1752-1759.	2.2	227
239	Renal denervation for resistant hypertensionâ€”the Symplicity HTN-1 study â€” Authors' reply. Lancet, The, 2014, 383, 1885-1886.	13.7	4
240	Potential future denervation targets. Interventional Cardiology, 2014, 6, 569-579.	0.0	0
241	From SYMPPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go?. EuroIntervention, 2014, 10, 21-23.	3.2	26
242	Renal Denervation And Pulmonary Vein Isolation In Patients With Drug Resistant Hypertension And Symptomatic Atrial Fibrillation. Journal of Atrial Fibrillation, 2014, 7, 1165.	0.5	1
243	Renal Sympathetic Nerve Ablation for Treatment-Resistant Hypertension. British Journal of Clinical Pharmacology, 2013, 76, n/a-n/a.	2.4	14
244	International Expert Consensus Statement. Journal of the American College of Cardiology, 2013, 62, 2031-2045.	2.8	124
245	Blood Pressure and Sympathetic Nervous System Response to Renal Denervation. Hypertension, 2013, 61, e13.	2.7	10
246	Percutaneous transluminal renal denervation: A potential treatment option for polycystic kidney disease-related pain?. International Journal of Cardiology, 2013, 162, e58-e59.	1.7	23
247	Restoration of blood pressure control with pacemaker implantation in a patient with bradycardia and resistant hypertension: A case report. International Journal of Cardiology, 2013, 167, e38-e40.	1.7	5
248	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. International Journal of Cardiology, 2013, 168, 2214-2220.	1.7	122
249	Substantial Reduction in Single Sympathetic Nerve Firing After Renal Denervation in Patients With Resistant Hypertension. Hypertension, 2013, 61, 457-464.	2.7	331
250	The Relation of Glucose Metabolism to Left Ventricular Mass and Function and Sympathetic Nervous System Activity in Obese Subjects With Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E227-E237.	3.6	22
251	Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. International Journal of Hypertension, 2013, 2013, 1-9.	1.3	46
252	Effects of Acute and Chronic Stress on the L-Arginine Nitric Oxide Pathway in Black and White South Africans. Psychosomatic Medicine, 2013, 75, 751-758.	2.0	16



#	ARTICLE	IF	CITATIONS
253	Renal sympathetic nerve ablation for the management of resistant hypertension. Current Opinion in Nephrology and Hypertension, 2013, 22, 607-614.	2.0	5
254	Renal nerve ablation reduces augmentation index in patients with resistant hypertension. Journal of Hypertension, 2013, 31, 1893-1900.	0.5	66
255	Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension. Circulation, 2013, 128, 132-140.	1.6	240
256	Dyslipidemia Is Associated With Sympathetic Nervous Activation and Impaired Endothelial Function in Young Females. American Journal of Hypertension, 2013, 26, 250-256.	2.0	59
257	Dabigatran elimination: is haemodialysis effective?. Thrombosis and Haemostasis, 2013, 109, 580-581.	3.4	3
258	Rationale and design of a large registry on renal denervation: the Global SYMPPLICITY registry. EuroIntervention, 2013, 9, 484-492.	3.2	56
259	Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation. EuroIntervention, 2013, 9, R127-R135.	3.2	26
260	Devices for Hypertension. , 2013, , 230-235.		0
261	Cognitive performance in patients with resistant hypertension following renal sympathetic denervation. EuroIntervention, 2013, 9, 665-667.	3.2	0
262	Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ, The, 2012, 345, e7156-e7156.	6.0	33
263	Renal Denervation in Moderate to Severe CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1250-1257.	6.1	322
264	Neuroadrenergic Dysfunction Along the Diabetes Continuum. Diabetes, 2012, 61, 2506-2516.	0.6	101
265	Baseline Sympathetic Nervous System Activity Predicts Dietary Weight Loss in Obese Metabolic Syndrome Subjects. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 605-613.	3.6	36
266	Effects of renal denervation on insulin resistance. Expert Review of Cardiovascular Therapy, 2012, 10, 1381-1386.	1.5	10
267	Health-Related Quality of Life After Renal Denervation in Patients With Treatment-Resistant Hypertension. Hypertension, 2012, 60, 1479-1484.	2.7	72
268	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. Journal of Hypertension, 2012, 30, 1047-1055.	0.5	134
269	Facilitated defensive coping, silent ischaemia and ECG left-ventricular hypertrophy. Journal of Hypertension, 2012, 30, 543-550.	0.5	40
270	Ambulatory blood pressure monitoring in Australia. Journal of Hypertension, 2012, 30, 253-266.	0.5	109

#	ARTICLE	IF	CITATIONS
271	New drugs, procedures, and devices for hypertension. Lancet, The, 2012, 380, 591-600.	13.7	139
272	Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. Circulation, 2012, 126, 2976-2982.	1.6	420
273	Renal nerve ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies. International Journal of Cardiology, 2012, 159, e35-e36.	1.7	7
274	Catheter based radiofrequency ablation of renal nerves for the treatment of resistant hypertension. Italian Journal of Medicine, 2012, 6, 105-109.	0.3	1
275	Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension. Hypertension, 2012, 60, 419-424.	2.7	289
276	Effects of Renal Denervation on Sympathetic Activation, Blood Pressure, and Glucose Metabolism in Patients with Resistant Hypertension. Frontiers in Physiology, 2012, 3, 10.	2.8	67
277	Advances in Sympathetic Nerve Recording in Humans. Frontiers in Physiology, 2012, 3, 11.	2.8	9
278	The Role of Renal Denervation in the Treatment of Heart Failure. Current Cardiology Reports, 2012, 14, 285-292.	2.9	83
279	Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects. Current Hypertension Reports, 2012, 14, 247-253.	3.5	43
280	Does renalase degrade catecholamines?. Kidney International, 2011, 79, 1380.	5.2	23
281	Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension. Circulation, 2011, 123, 1940-1946.	1.6	541
282	Renal Denervation and Hypertension. American Journal of Hypertension, 2011, 24, 635-642.	2.0	63
283	Recent advances in the treatment of hypertension. Expert Review of Cardiovascular Therapy, 2011, 9, 729-744.	1.5	14
284	Change in sympathetic nerve firing pattern associated with dietary weight loss in the metabolic syndrome. Frontiers in Physiology, 2011, 2, 52.	2.8	28
285	Association of (pro)renin receptor gene polymorphism with blood pressure in Caucasian men. Pharmacogenetics and Genomics, 2011, 21, 347-349.	1.5	32
286	Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. Journal of Hypertension, 2011, 29, 553-564.	0.5	93
287	Renal denervation: a potential new treatment modality for polycystic ovary syndrome?. Journal of Hypertension, 2011, 29, 991-996.	0.5	124
288	Single-unit muscle sympathetic nervous activity and its relation to cardiac noradrenaline spillover. Journal of Physiology, 2011, 589, 2597-2605.	2.9	53

#	ARTICLE	IF	CITATIONS
289	Folic Acid Treatment Normalizes NOSâ€œDependence of Vascular Tone in the Metabolic Syndrome. Obesity, 2011, 19, 960-967.	3.0	13
290	Sympatho-renal axis in chronic disease. Clinical Research in Cardiology, 2011, 100, 1049-1057.	3.3	155
291	Novel procedure- and device-based strategies in the management of systemic hypertension. European Heart Journal, 2011, 32, 537-544.	2.2	47
292	Sympathetic Activation in Chronic Kidney Disease. Hypertension, 2011, 57, 683-685.	2.7	28
293	Reduction in Basal Nitric Oxide Activity Causes Albuminuria. Diabetes, 2011, 60, 572-576.	0.6	24
294	The Effects of Weight Loss<i>Versus</i>Weight Loss Maintenance on Sympathetic Nervous System Activity and Metabolic Syndrome Components. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E503-E508.	3.6	97
295	Response to Letter Regarding Article, â€œEffect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Studyâ€. Circulation, 2011, 124, .	1.6	0
296	Relation between QT interval variability and cardiac sympathetic activity in hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1412-H1417.	3.2	80
297	Recurrent Postural Vasovagal Syncope. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 711-718.	4.8	46
298	Device-Based Antihypertensive Therapy. Circulation, 2011, 123, 209-215.	1.6	136
299	Chrelin Modulates Sympathetic Nervous System Activity and Stress Response in Lean and Overweight Men. Hypertension, 2011, 58, 43-50.	2.7	70
300	Surgical approaches to the treatment of obesity. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 429-437.	17.8	64
301	Association between the sympathetic firing pattern and anxiety level in patients with the metabolic syndrome and elevated blood pressure. Journal of Hypertension, 2010, 28, 543-550.	0.5	95
302	European Society of Hypertension Working Group on Obesity Antihypertensive effects of weight loss: myth or reality?. Journal of Hypertension, 2010, 28, 637-643.	0.5	39
303	The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertension Research, 2010, 33, 521-528.	2.7	90
304	Renal Sympathetic Nerve Ablation: The New Frontier in the Treatment of Hypertension. Current Hypertension Reports, 2010, 12, 39-46.	3.5	41
305	New Therapeutic Approaches to Resistant Hypertension. Current Hypertension Reports, 2010, 12, 296-302.	3.5	12
306	Sympathetic nervous activation in obesity and the metabolic syndromeâ€œCauses, consequences and therapeutic implications. , 2010, 126, 159-172.		267

#	ARTICLE	IF	CITATIONS
307	Rebuttal from Esler, Lambert, and Schlaich. Journal of Applied Physiology, 2010, 109, 2000-2001.	2.5	0
308	Stress Reactivity and Its Association With Increased Cardiovascular Risk: A Role for the Sympathetic Nervous System?. Hypertension, 2010, 55, e20; author reply e21.	2.7	13
309	Sympathetic Neural Adaptation to Hypocaloric Diet With or Without Exercise Training in Obese Metabolic Syndrome Subjects. Diabetes, 2010, 59, 71-79.	0.6	104
310	Sympathetic Nervous System Activity Is Associated With Obesity-Induced Subclinical Organ Damage in Young Adults. Hypertension, 2010, 56, 351-358.	2.7	174
311	Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?. Journal of Hypertension, 2010, 28, 1809-1810.	0.5	8
312	Point: Chronic Activation of the Sympathetic Nervous System is the Dominant Contributor to Systemic Hypertension. Journal of Applied Physiology, 2010, 109, 1996-1998.	2.5	113
313	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2) Trial. Journal of the American College of Cardiology, 2010, 55, 257-265.	13.7	2,002
314	Weight Loss May Reverse Blunted Sympathetic Neural Responsiveness to Glucose Ingestion in Obese Subjects With Metabolic Syndrome. Diabetes, 2009, 58, 1126-1132.	0.6	51
315	Sympathetic Activation in Chronic Renal Failure. Journal of the American Society of Nephrology: JASN, 2009, 20, 933-939.	6.1	371
316	Blunted sympathetic neural response to oral glucose in obese subjects with the insulin-resistant metabolic syndrome. American Journal of Clinical Nutrition, 2009, 89, 27-36.	4.7	90
317	Renal Vascular Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus. American Journal of Kidney Diseases, 2009, 53, 281-289.	1.9	37
318	Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension. New England Journal of Medicine, 2009, 361, 932-934.	27.0	702
319	Renal Denervation as a Therapeutic Approach for Hypertension. Hypertension, 2009, 54, 1195-1201.	2.7	220
320	Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet, The, 2009, 373, 1275-1281.	13.7	1,918
321	Renal sympathetic denervation for resistant hypertension – Authors' reply. Lancet, The, 2009, 373, 2109-2110.	13.7	2
322	Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. Journal of Hypertension, 2009, 27, 2201-2208.	0.5	42
323	European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. Journal of Hypertension, 2009, 27, 207-211.	0.5	37
324	Human Sympathetic Nerve Biology. Annals of the New York Academy of Sciences, 2008, 1148, 338-348.	3.8	84

#	ARTICLE	IF	CITATIONS
325	CHRONIC MENTAL STRESS IS A CAUSE OF ESSENTIAL HYPERTENSION: PRESENCE OF BIOLOGICAL MARKERS OF STRESS. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 498-502.	1.9	134
326	SINGLE-UNIT SYMPATHETIC DISCHARGE PATTERN IN PATHOLOGICAL CONDITIONS ASSOCIATED WITH ELEVATED CARDIOVASCULAR RISK. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 503-507.	1.9	39
327	Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis, 2008, 196, 704-711.	0.8	28
328	Altered Sympathetic Nervous Reactivity and Norepinephrine Transporter Expression in Patients With Postural Tachycardia Syndrome. Circulation: Arrhythmia and Electrophysiology, 2008, 1, 103-109.	4.8	79
329	Elevated Cardiac Risk in Patients With Major Depressive Disorder. American Journal of Psychiatry, 2008, 165, 137-137.	7.2	1
330	Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. Journal of Hypertension, 2008, 26, 110-116.	0.5	24
331	Analysis of retinal arteriolar structure in never-treated patients with essential hypertension. Journal of Hypertension, 2008, 26, 1427-1434.	0.5	90
332	Differing Pattern of Sympathoexcitation in Normal-Weight and Obesity-Related Hypertension. Hypertension, 2007, 50, 862-868.	2.7	181
333	Letter by Schlaich et al Regarding Article, "Relationship Between Central Sympathetic Drive and Magnetic Resonance Imaging-Determined Left Ventricular Mass in Essential Hypertension"; Circulation, 2007, 116, e416; author reply e417.	1.6	0
334	Increased Wall:Lumen Ratio of Retinal Arterioles in Male Patients With a History of a Cerebrovascular Event. Hypertension, 2007, 50, 623-629.	2.7	139
335	Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk?. Journal of Hypertension, 2007, 25, 2117-2124.	0.5	259
336	Gender differences in sympathetic nervous activity: influence of body mass and blood pressure. Journal of Hypertension, 2007, 25, 1411-1419.	0.5	108
337	Involvement of endothelial mechanisms in L-arginine-induced alterations of renal haemodynamics in humans. Journal of Hypertension, 2007, 25, 1515-1516.	0.5	7
338	Left-Ventricular Structure and Function Are Influenced by Angiotensinogen Gene Polymorphism (â~20) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.6	7
339	Effects of nitric oxide synthase inhibition and l-arginine on renal haemodynamics in young patients at high cardiovascular risk. Atherosclerosis, 2007, 192, 155-160.	0.8	5
340	Renin-angiotensin system and cardiovascular risk. Lancet, The, 2007, 369, 1208-1219.	13.7	583
341	Rapid Nongenomic Effects of Aldosterone on the Renal Vasculature in Humans. Hypertension, 2006, 47, 650-655.	2.7	62
342	The neuronal noradrenaline transporter, anxiety and cardiovascular disease. Journal of Psychopharmacology, 2006, 20, 60-66.	4.0	73

#	ARTICLE	IF	CITATIONS
343	Angiotensin II and norepinephrine release: interaction and effects on the heart. Journal of Hypertension, 2005, 23, 1077-1082.	0.5	23
344	Impaired L-Arginine Transport and Endothelial Function in Hypertensive and Genetically Predisposed Normotensive Subjects. Circulation, 2004, 110, 3680-3686.	1.6	120
345	Sympathetic Augmentation in Hypertension. Hypertension, 2004, 43, 169-175.	2.7	451
346	Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E744-E752.	3.5	58
347	Adrenoceptor-mediated, nitric-oxide-dependent vasodilatation is abnormal in early hypertension. Journal of Hypertension, 2004, 22, 1917-1925.	0.5	14
348	Interactions Between Leptin and the Human Sympathetic Nervous System. Hypertension, 2003, 41, 1072-1079.	2.7	223
349	Relation Between Cardiac Sympathetic Activity and Hypertensive Left Ventricular Hypertrophy. Circulation, 2003, 108, 560-565.	1.6	393
350	Hypercholesterolaemia and treatment with statins do not alter L-arginine-induced changes of renal haemodynamics. Nephrology Dialysis Transplantation, 2002, 17, 1758-1765.	0.7	10
351	Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. Journal of Hypertension, 2002, 20, 117-124.	0.5	28
352	Sympathetic and cardiac baroreflex function in panic disorder. Journal of Hypertension, 2002, 20, 2445-2451.	0.5	57
353	Assessment of endothelial function of the renal vasculature in human subjects. American Journal of Hypertension, 2002, 15, 3-9.	2.0	75
354	Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. Journal of the American College of Cardiology, 2001, 37, 1351-1358.	2.8	103
355	Impaired Sodium Excretion During Mental Stress in Mild Essential Hypertension. Hypertension, 2001, 37, 923-927.	2.7	27
356	Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. Clinical Science, 2000, 98, 521-529.	4.3	23
357	Is L-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. Clinical Science, 2000, 99, 293-302.	4.3	29
358	Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. Clinical Science, 2000, 98, 521.	4.3	12
359	Is L-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. Clinical Science, 2000, 99, 293.	4.3	9
360	PROSPECTIVE ANALYSIS OF THE VALUE OF 24-HOUR AMBULATORY BLOOD PRESSURE ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION. Transplantation, 2000, 70, 819-827.	1.0	41

#	ARTICLE	IF	CITATIONS
361	Effects of oral contraceptives on vascular endothelium in premenopausal women. American Journal of Obstetrics and Gynecology, 2000, 183, 28-33.	1.3	33
362	Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. American Journal of Cardiology, 2000, 85, 1199-1206.	1.6	56
363	Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients. Atherosclerosis, 2000, 153, 383-389.	0.8	34
364	1166 A/C Polymorphism of the Angiotensin II Type 1 Receptor Gene and the Response to Short-Term Infusion of Angiotensin II. Circulation, 1999, 100, 1394-1399.	1.6	55
365	Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. Supportive Care in Cancer, 1999, 7, 354-361.	2.2	43
366	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. American Journal of Hypertension, 1999, 12, 418-422.	2.0	0
367	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. American Journal of Hypertension, 1999, 12, 418-422.	2.0	24
368	Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects. American Heart Journal, 1999, 138, 810-817.	2.7	25
369	Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. Journal of Hypertension, 1999, 17, 1933-1939.	0.5	21
370	Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach Focus on treatment by antihypertensive agents. American Journal of Hypertension, 1998, 11, 1394-1404.	2.0	59
371	Does Lipoprotein(a) Impair Endothelial Function?. Journal of the American College of Cardiology, 1998, 31, 359-365.	2.8	56
372	Increased Bioavailability of Nitric Oxide After Lipid-Lowering Therapy in Hypercholesterolemic Patients. Circulation, 1998, 98, 211-216.	1.6	234
373	Renal and Systemic Hemodynamics in Black and White Hypertensive Patients. American Journal of Hypertension, 1997, 10, 971-978.	2.0	4
374	Catheter based radiofrequency ablation of renal nerves for the treatment of resistant hypertension. Italian Journal of Medicine, 0, , 105-109.	0.3	0